Download Free Medical Medication Management for Older Adults PowerPoint Presentation

Medication Management for Older Adults PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Adverse Drug Events, which is titled "Medication Management for Older Adults", to know about the physiologic changes associated with normal aging that influence pharmacokinetics and pharmacodynamics, avoiding potentially harmful medications for older adults, recognize Adverse Drug Events (ADEs) when an older adult presents with a new condition or complaint, and the strategies for evaluating starting and stopping medications.

Tags : Adverse Drug Events, Medication Management, Older Adults, aging, pharmacokinetics, pharmacodynamics

Published on : Jul 20, 2021 | Views : 2149 | Downloads : 7

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Medication Management forOlder Adults Anthony J. Caprio, MD, CMD Medical Director, Division of Aging Department of Family Medicine
Slide 2-

Objectives Identify the physiologic changes associated with normal aging that influence pharmacokinetics and pharmacodynamics Avoid potentially harmful medications for older adults Recognize Adverse Drug Events (ADEs) when an older adult presents with a new condition or complaint Utilize strategies for evaluating starting and stopping medications
Slide 3-

Challenges of Prescribingfor Older Adults Multiple medical conditions Multiple medications Multiple prescribers Different metabolisms and responses Adherence and cost Supplements, herbals, and OTC drugs 3 Lancet. 1995;346(8966):32–36.
Slide 4-

Lots of Medications and Little Evidence 2/3 of older adults are on regular medications Adults age >65 account for 1/3 of all prescriptions, but only represent 15% of the US population Older adults are frequently not included in clinical trials, which makes it difficult to predict drug metabolism or drug effects 4 Health Care Financ Rev. 1990;11:1-41.
Slide 5-

Adverse Drug Events (ADEs) Adverse symptoms Adverse clinical outcomes Doctor visits or hospitalizations Falls Functional decline Changes in cognition (delirium) Death Poor adherence, poor quality of life Increased cost 5
Slide 6-

Physiologic Changes with Normal Aging Less Water More Fat Less muscle mass Slowed hepatic metabolism Decreased renal excretion Decreased responsiveness and sensitivity of the baroreceptor reflex 6
Slide 7-

Absorption Not affected by the normal aging process Can be altered by drug interactions Antacids Iron Can be affected by disease Lack of intrinsic factor (B12 absorption) Delayed gastric emptying 7
Slide 8-

Distribution Less water = ↓ volume of distribution Higher concentration of water soluble drugs More fat = ↑ volume of distribution Prolonged action of fat-soluble drugs (increased half-life) Lower serum proteins (like albumin) increases the concentration of unbound (free or active) form of drugs 8
Slide 9-

Metabolism Slowed Phase I, cytochrome P450, reactions Oxidation, reduction, dealkylation Warfarin and phenytoin levels may be higher because of altered metabolism Phase II reactions are essentially unchanged Conjugation, acetylation, methylation Drug-drug interactions Increased risk with increased number of drugs 9
Slide 10-

Excretion Hepatic Renal Renal clearance may be reduced Serum creatinine may not be an accurate reflection of renal clearance in elderly patients. (decreased lean body mass) Active drug metabolites may accumulate Prolonged therapeutic action Adverse effects 10
Slide 11-

Physiologic ChangesAssociated with Disease States Cardiac Disease Impaired cardiac output (decreased absorption, metabolism, clearance) Greater susceptibility to cardiac adverse effects Kidney and Liver Disease Decreased drug clearance and altered metabolism Neurological Diseases Diminished neurotransmitter levels Greater susceptibility to neurological effects 11
Slide 12-

JAMA. 2010;304(14):1592-1601. Ann Intern Med. 2007;147:755-765.
Slide 13-

Beers Criteria Potentially inappropriate medications for older adults. Originally conceived by Dr. Mark Beers Published in 1991, revised in 1997, 2002, and 2012. Consensus-based, but statistical association with adverse drug events Adopted for nursing home regulation. Does not account for the complexity of a patient’s entire medication regimen. 13 J Am Geriatr Soc 60:616–631, 2012.
Slide 14-

AGS Beers Criteria Resources http://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/2012
Slide 15-

Beers Criteria: Anticholinergic Medications Antihistamines (1st generation) Diphenhydramine (Benadryl, Unisom, Tylenol PM, Advil PM) Hydroxyzine (Atarax, Vistaril) Promethazine (Phenergan) Antispasmodics Dicyclomine (Bentyl) Hyoscyamine (Levsin) Scopolamine (Transderm Scop) Skeletal Muscle Relaxants Carisoprodol (Soma) Cyclobenzaprine (Flexeril) Methocarbamol (Robaxin) Tricyclic Antidepressants Amitriptyline (Elavil) Doxepin (Sinequan) J Am Geriatr Soc 60:616–631, 2012. See Table 2.
Slide 16-

Beers Criteria: Benzodiazepines Increased sensitivity for older adults Slowed metabolism, especially long-acting agents Similar neurocognitive effects to alcohol May cause a paradoxical reaction (increased agitation) Increased risk of adverse clinical events Falls and fractures Cognitive impairment Delirium Avoid if possible Appropriate if being used for seizures, alcohol withdrawal, severe anxiety, or periprocedural anesthesia If necessary, use lowest dose possible 16 J Am Geriatr Soc 60:616–631, 2012. See Table 2.
Slide 17-

Beers Criteria: Sedative-Hypnotics Nonbenzodiazepine Hypnotics Eszopiclone (Lunesta) Zolpidem (Ambien) Zaleplon (Sonata) Benzodiazepine-receptor agonists Adverse events similar to those of benzodiazepines Increased risk for delirium, falls fractures J Am Geriatr Soc 60:616–631, 2012. See Table 2.
Slide 18-

Beers Criteria: Antipsychotic Medications FDA “Black Box” warning: increased risk of death, mostly due to cardiovascular events (eg. heart failure, sudden death) and infections (eg. pneumonia) Avoid using for behavioral problems associated with dementia Try non-pharmacologic interventions Reserve for threat to self or others Typical (First Generation, Conventional) Haloperidol (Haldol) Prochlorperazine (Compazine) Atypical (Second Generation) Risperdone (Risperdal) Quetiapine (Seroquel) Olanzepine (Zyprexa) Ziprasidone (Geodon) Aripiprazole (Abilify) Adverse Effects Arrhythmias (QT prolongation) Abnormal Movements (Parkinsonism, tardive dyskinesia) 18 J Am Geriatr Soc 60:616–631, 2012. See Table 2.
Slide 19-

Beers Criteria: Pain Medications Non–COX-selective NSAIDs GI bleeding and peptic ulcer disease Avoid chronic use Indomethacin and Ketorolac (Toradol) Higher risk of GI, renal, and CNS effects Meperidine (Demerol) Can cause neurotoxicity Safer alternatives available 19 J Am Geriatr Soc 60:616–631, 2012. See Table 2.
Slide 20-

Before You Prescribe Question the need for new medications Stop medications, whenever possible Prioritize treatments Weigh risks and benefits Avoid undertreating older patients Pain Systolic hypertension (stroke, renal failure, CHF) Anticoagulation and atrial fibrillation (stroke) 20 Drugs Aging 2003; 20: 23-57. Lancet 2000; 355: 865–872. Ann Intern Med 1999;131:492-501. J Gen Intern Med 2005; 20:116–122.
Slide 21-

“Start Low and Go Slow…” Start one medication at a time. Start with a low dose and increase gradually. Once daily is usually best. Monitor for response and adverse effects. Assess adherence with regimen.
Slide 22-

“…But, Go All The Way!” Be conservative, but don’t miss the target! What is your goal? Are you achieving it? Can you keep increasing the dose or are you limited by side effects? Are you observing a clinical benefit at lower doses? Consider stopping if you can’t “go all the way” and the benefit is not clear.
Slide 23-

“Deprescribing” “Systematic process of identifying and discontinuing drugs in instances in which existing or potential harms outweigh existing or potential benefits within the context of an individual patient’s care goals, current level of functioning, life expectancy, values, and preferences.” JAMA Intern Med. 2015;175(5):827-834
Slide 24-

“Deprescribing” Should Be Considered New symptom or clinical syndrome suggestive of ADE Advanced disease, terminal illness, extreme frailty High-risk drugs or combinations Preventive drugs for scenarios associated with no increased risk despite stopping drug Stopping alendronate after 5 years of treatment results Stopping statins for primary prevention Patient/family willing to participate in shared decision JAMA Intern Med. 2015;175(5):827-834
Slide 25-

“Deprescribing” Instruct patient to bring all medications to visit (prescription and non-prescription) What Are Current Indications for Each Drug? Is the Patient Actually Taking the Drug? Does the Likely Benefit of the Drug Outweigh Its Potential for Harm? High-risk medications (see Beers Criteria) Time to benefit for preventive medications JAMA Intern Med. 2015;175(5):827-834
Slide 26-

Cases
Slide 27-

Case 1: Mr. Johnson What physiologic change associated with normal aging may affect Mr. Johnson’s clinical response to medications? b) Decreased responsiveness of the carotid baroreceptors
Slide 28-

28 Case 1: Mr. Johnson Which of the following is the best explanation for his overall clinical presentation? b) Acute urinary retention due to anticholinergic effects of diphenyhydramine and orthostatic hypotension from the doxazosin Urinary Retention Parasympathetic nervous system mediates detrusor muscle contraction Blocked by anticholinergic medications like diphenhydramine Orthostatic Hypotension α -adrenergic agonists help to relax the urethral sphincter α-adrenergic agonists also decreases systemic vascular resistance and can cause hypotension
Slide 29-

Case 2: Mr. Jones What physiologic change associated with normal aging may affect Mr. Jones’ clinical response to medications? c) Prolonged half-life of lipid-soluble drugs due to a higher relative composition of body fat compared to younger individuals
Slide 30-

Case 2: Mr. Jones Which of the following is the best explanation for his overall clinical presentation? b) Anticholinergic effects of the promethazine precipitated delirium, and the lorazepam had a paradoxical effect.
Slide 31-

Case 3: Mrs. Smith After ruling-out an underlying urinary tract infection, you should c) reduce or discontinue the donepezil (Aricpet)
Slide 32-

Prescribing Cascade:Pharmacologic Tug-of-War Tolterodine (Detrol) potent anticholinergic Relaxes detrusor muscle to treat urge incontinence Donepezil (Aricept) acetylcholinesterase inhibitor Raises acetylcholine levels to help improve cognition Can cause detrusor hyperactivity Incontinence Dementia is a risk factor Possible ADE related to Donepezil 32 Arch Intern Med 2005; 165:808-813.
Slide 33-

Case 3: Mrs. Smith If Mrs. Smith developed bradycardia after starting the donepezil (Aricept), what is the most likely mechanism? c) Increased tone of the vagus nerve Donepezil (Aricept) acetylcholinesterase inhibitor Raises acetylcholine levels throughout nervous system Increases vagal tone Could cause symptomatic bradycardia
Slide 34-

Case 4: Mrs. Green Mrs. Green is at risk for which of the following adverse drug events (ADEs)? d) All of the above Hypotension: diuretics, antihypertensives Hyperkalemia: ACE-I and spironolactone Bleeding: ASA, clopidogrel, warfarin
Slide 35-

Case 4: Mrs. Green All of the following medications for Mrs. Green are listed in the 2012 Beers Criteria as potentially inappropriate medications for older adults EXCEPT: c) Metoprolol tartrate (Lopressor) 25mg po BID
Slide 36-

Beers Criteria (2012) Digoxin (Lanoxin) > 0.125 mg/day Higher dosages associated with no additional benefit and may increase risk of toxicity Slow renal clearance may lead to risk of toxic effects Dronedarone (Multaq) Worse outcomes reported in patients with permanent atrial fibrillation or heart failure In general, rate control is preferred over rhythm control Spironolactone (Aldactone) >25mg/day Higher risk of hyperkalemia at higher doses (especially if taking NSAID, ACE-I, ARB, or K+ supplement) Avoid in patients CrCl < 30 mL/min
Slide 37-

37